Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please in Korean Patients With Coronary In-stent Restenosis

• Age ≥19 years old
• Patients with significant coronary artery stenosis including left main coronary lesion (> 50% diameter stenosis on coronary angiography)
• Patients with stable angina pectoris, or unstable angina pectoris, and asymptomatic myocardial ischemia
• Patients suitable to receive coronary revascularization of any type
• Restenosis Mehran type I-III after stent implantation for the first time
• Patients with In-stent restenosis after 90 days of the stent implantation, and the degree of restenosis corresponds to Mehran type I-Ⅲ.
• Diameter of the stent with restenosis should be 2.0-4.0mm (included). Length of the stenosis lesion should be no more than 40mm
• In case of voluntarily deciding to participate in this clinical trial by signing the informed consent form

Exclusion Criteria:

• Patients with Infarct related artery (IRA) lesions among patients with acute myocardial infarction
• Patients have restenosis lesions with thrombosis
• Patients with a history of cardiogenic shock
• Patients with total occlusion indicating TIMI 0 blood flow at the target lesion (Mehran type IV stenosis)
• Patients with graft vessel lesion
• Patients who are contraindicated in aspirin, heparin, clopidogrel, ticlopidine, and paclitaxel
• Patients with renal insufficiency (eGFR\<30mL/min)
• Pregnant or lactating women
• The patients have a life expectancy of less than 12 months
• Patients who had reduced immunity or clinically significant abnormalities in the laboratory tests (hematological, serum biochemical, and urine tests) performed at the time of screening
• Patients who had clinically significant disorders in cardiovascular system, digestive system, respiratory system, endocrine system, and central nervous system, or mental illness that significantly affects this study
• Patients who are unsuitable for the study according to the investigator judges